Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Incyte Corp
(NQ:
INCY
)
64.14
+1.12 (+1.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corp
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
April 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,...
Via
Benzinga
Multiple Abstracts from Incyte’s Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience
April 20, 2021
From
Incyte
Via
Business Wire
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Exposures
Product Safety
Incyte to Present at Upcoming Investor Conference
April 27, 2021
From
Incyte
Via
Business Wire
Incyte Announces New Ruxolitinib Data From Atopic Dermatitis and Vitiligo Studies
April 23, 2021
Incyte Corporation (NASDAQ: INCY) has announced findings from three pooled analyses of its Phase 3 studies, TRuE-AD1 and TRuE-AD2 evaluating ruxolitinib cream...
Via
Benzinga
Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
April 23, 2021
From
Incyte
Via
Business Wire
Incyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis
April 23, 2021
From
Incyte
Via
Business Wire
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
April 19, 2021
From
Incyte and MorphoSys AG
Via
Business Wire
Incyte to Report First Quarter Financial Results
April 13, 2021
From
Incyte
Via
Business Wire
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
April 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) Aclaris Therapeutics, Inc...
Via
Benzinga
Exposures
Product Safety
Eli Lilly-Incyte's Baricitinib Study In Hospitalized COVID-19 Patients Fails To Meet Main Goal
April 08, 2021
Eli Lilly And Co (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) have reported results from the COV-BARRIER Phase 3 study ...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award
April 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 6) AngioDynamics, Inc. (NASDAQ...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.